AI Article Synopsis
- * This study analyzed data from The Cancer Genome Atlas to investigate the effects of HOOK3 gene amplification on gene expression and patient survival in BUC, finding that HOOK3 amplification is associated with distinct gene changes and potential tumor suppression mechanisms.
- * The results suggest that HOOK3 amplification may improve survival rates in BUC patients, indicating a protective role; however, more research is necessary to fully understand its mechanisms and therapeutic potential.
Article Abstract
Background/aim: Bladder urothelial carcinoma (BUC) poses a significant health challenge, ranking as the fourth most common cancer among men in the United States, with a mortality rate of approximately 20%. Genetic abnormalities such as mutations in the telomerase reverse transcriptase (TERT) gene and loss of heterozygosity (LOH) on chromosome 9 are commonly observed in BUC; however, many genes involved remain unidentified. This study aimed to explore the role of HOOK3 in BUC and its impact on survival.
Materials And Methods: Using data from The Cancer Genome Atlas (TCGA) and cBioPortal, we performed differential gene expression and survival analyses to compare the patients with and without HOOK3 amplification.
Results: Our findings revealed that 2.2% of genes were up-regulated and 5.3% down-regulated in the HOOK3-amplified group. These changes suggest that HOOK3 amplification is linked to distinct gene expression patterns, with a higher proportion of down-regulated genes. Pathway enrichment related to chromatin remodeling, ion transport, and mitochondrial function suggests that HOOK3 may promote genomic stability and transcriptional regulation, contributing to tumor suppression. The involvement of mitochondrial and ribosomal pathways in protein synthesis and chromosome segregation may also protect against chromosomal abnormalities and uncontrolled cell growth. HOOK3 amplification appears to correlate with improved patient survival.
Conclusion: These results suggest a potential protective role of HOOK3 amplification in BUC. Further research is needed to explore the underlying mechanisms and their therapeutic potential for reducing BUC-related mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.17343 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HOOK3 Amplification in Bladder Urothelial Carcinoma: Insights from Gene Expression and Survival Analysis.
Anticancer Res
December 2024
Department of Medicine, Division of Hematology & Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, U.S.A.;
Article Synopsis
- * This study analyzed data from The Cancer Genome Atlas to investigate the effects of HOOK3 gene amplification on gene expression and patient survival in BUC, finding that HOOK3 amplification is associated with distinct gene changes and potential tumor suppression mechanisms.
- * The results suggest that HOOK3 amplification may improve survival rates in BUC patients, indicating a protective role; however, more research is necessary to fully understand its mechanisms and therapeutic potential.
NTRK-fused central nervous system tumours: clinicopathological and genetic insights and response to TRK inhibitors.
Acta Neuropathol Commun
July 2024
Department of Pathology, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, Republic of Korea.
Article Synopsis
- NTRK gene fusions occur in about 1% of gliomas and are considered promising targets for treatment due to their ability to cross the blood-brain barrier, leading to interest in TRK inhibitors.
- A study of 12 NGS-verified NTRK-fused gliomas at Seoul National University Hospital found that DLGGs mostly had only NTRK fusions, while DHGGs often had additional genetic mutations, with various fusion partners identified for NTRK1 and NTRK2.
- Treatment outcomes using TRK inhibitors varied significantly; one child with DLGG showed stable disease, while a child with DHGG and an adult with glioblastoma experienced tumor recurrence and progression, highlighting the mixed
Whole genome sequencing of HER2-positive metastatic extramammary Paget's disease: a case report.
Orphanet J Rare Dis
June 2024
Cancer Discovery Hub, National Cancer Centre Singapore, Singapore, Singapore.
Article Synopsis
- Extramammary Paget's disease (EMPD) is a rare skin cancer that mostly occurs in areas with many apocrine glands, like the vulva and scrotum, and the study aims to connect clinical data with genetic analysis of aggressive EMPD that responds to HER2-targeted treatments.
- Immunohistochemical analysis showed HER2 overexpression in tumors, and whole genome sequencing revealed significant copy number gains on chromosomes 7 and 8, particularly in genes associated with cancer, although the ERBB2 gene did not show high gains despite many tumor cells being HER2-positive.
- The analysis indicates that there are alternative signaling pathways involved, suggesting that these pathways may interact with HER2 signaling, contributing to the cancer's
KAT6A amplifications are associated with shorter progression-free survival and overall survival in patients with endometrial serous carcinoma.
PLoS One
October 2020
Department of Hematopathology, Section of Clinical Cytogenetics, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
Somatic copy number alterations (CNA) are common in endometrial serous carcinoma (ESC). We used the Tumor Cancer Genome Atlas Pan Cancer dataset (TCGA Pan Can) to explore the impact of somatic CNA and gene expression levels (mRNA) of cancer-related genes in ESC. Results were correlated with clinico-pathologic parameters such as age of onset, disease stage, progression-free survival (PFS) and overall survival (OS) (n = 108).
View Article and Find Full Text PDFThe genomic landscape of small intestine neuroendocrine tumors.
J Clin Invest
June 2013
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Small intestine neuroendocrine tumors (SI-NETs) are the most common malignancy of the small bowel. Several clinical trials target PI3K/Akt/mTOR signaling; however, it is unknown whether these or other genes are genetically altered in these tumors. To address the underlying genetics, we analyzed 48 SI-NETs by massively parallel exome sequencing.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!